TENUATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TENUATE (TENUATE).
Tenuate (diethylpropion) is a sympathomimetic amine that acts as an appetite suppressant. It stimulates the release of norepinephrine and to a lesser extent dopamine from presynaptic nerve terminals in the hypothalamus, increasing satiety.
| Metabolism | Extensively metabolized in the liver via N-dealkylation to active metabolites (ethylaminopropiophenone and diethylaminopropiophenone). Enzymes involved include CYP3A4 and CYP2D6. |
| Excretion | Renal (90% as metabolites, ~10% unchanged); minor biliary/fecal (<10%) |
| Half-life | 4-6 hours (terminal); clinical context: short half-life supports multiple daily dosing |
| Protein binding | ~92% (primarily albumin) |
| Volume of Distribution | ~4 L/kg (extensive tissue distribution, including CNS) |
| Bioavailability | Oral: ~60-70% (first-pass metabolism) |
| Onset of Action | Oral: 30-60 minutes; IV: immediate; IM: 15-30 minutes |
| Duration of Action | 4-6 hours (oral); clinical notes: anorectic effect lasts 4-6 hours, requiring multiple daily doses |
| Molecular Weight | 273.84 |
25 mg orally three times daily before meals, or 75 mg extended-release orally once daily in the morning.
| Dosage form | TABLET |
| Renal impairment | No specific guidelines; use with caution in severe renal impairment (GFR <30 mL/min) due to potential accumulation. |
| Liver impairment | Contraindicated in Child-Pugh Class C; use with caution in Class A and B, consider dose reduction. |
| Pediatric use | Not recommended for children under 16 years of age. |
| Geriatric use | Initial dose at 12.5 mg twice daily; titrate slowly due to increased sensitivity and risk of adverse effects. |
| 1st trimester | Data insufficient; potential risk of teratogenicity based on animal studies; use only if benefit outweighs risk. |
| 2nd trimester | Avoid; may cause fetal tachycardia, growth restriction; consider alternative therapies. |
| 3rd trimester | Avoid; risk of neonatal withdrawal, tachycardia, and growth restriction. |
Clinical note
Comprehensive clinical and safety monograph for TENUATE (TENUATE).
| Placental transfer | Crosses placenta; evidence based on molecular weight and lipid solubility; limited human data. |
| Breastfeeding | Excreted into breast milk in small amounts; potential for infant stimulation, irritability, and poor feeding; monitor infant for adverse effects. Use caution, especially in premature infants or prolonged exposure. |
■ FDA Black Box Warning
There is no FDA boxed warning for Tenuate.
| Serious Effects |
Hypersensitivity to diethylpropionHistory of drug abuseConcomitant MAOI use or within 14 daysHyperthyroidismSevere hypertensionCardiovascular disease (e.g., arrhythmias, unstable angina)GlaucomaAgitated statesPheochromocytoma
| Precautions | Primary pulmonary hypertension: rare but serious condition associated with use., Cardiac valvulopathy: risk increases with prolonged use or combination with other serotonergic drugs., Tachyphylaxis: tolerance to anorectic effects may develop within a few weeks., Psychiatric effects: may exacerbate psychiatric disorders, particularly in patients with history of substance abuse., Seizures: risk increased in patients with epilepsy or history of seizures. |
| Food/Dietary | Avoid caffeine and other stimulants (e.g., in coffee, tea, cola, energy drinks) as they may increase cardiovascular side effects. Avoid high-tyramine foods (e.g., aged cheeses, cured meats, fermented products) if also taking MAOIs, but this is relevant only if transitioning therapy. No specific food restrictions otherwise, but a reduced-calorie diet is essential for efficacy. |
Loading safety data…
| Lactation Rating |
| L3 - Moderately Safe |
| Teratogenic Risk | First trimester: Limited human data, but animal studies suggest increased risk of cardiovascular and neural tube defects. Second and third trimesters: Associated with reduced fetal growth and neonatal withdrawal symptoms (tremors, hypertonia, feeding difficulties). Avoid use unless clearly needed. |
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and weight. Assess fetal growth via ultrasound if used long-term. Monitor neonate for withdrawal symptoms if used near term. |
| Fertility Effects | Not formally studied in humans. In animal studies, no significant impact on fertility reported. Potential for menstrual irregularities in women due to CNS stimulation. |
| Clinical Pearls | Tenuate (diethylpropion) is a sympathomimetic amine anorectic indicated for short-term (8-12 weeks) adjunct in obesity management. Avoid in patients with history of drug abuse, cardiovascular disease, hyperthyroidism, or glaucoma. Monitor blood pressure and heart rate regularly. Tolerance may develop; discontinue if tolerance occurs. Contraindicated with MAOIs or within 14 days of their use. May impair ability to drive or operate machinery. |
| Patient Advice | Take exactly as prescribed; do not increase dose or duration. · May cause dizziness or blurred vision; avoid driving if affected. · Inform your doctor if you have heart disease, high blood pressure, or thyroid problems. · Avoid alcohol and other CNS stimulants while taking this medication. · Report any chest pain, palpitations, or severe headache immediately. · Do not take with other appetite suppressants without consulting your doctor. · This medication is only for short-term use; combine with diet and exercise. |